Balyasny Asset Management’s Faeth Therapeutics FTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$34.3M Buy
1,153,377
+111,179
+11% +$3.46M 0.04% 536
2026
Q2
$26.1M Buy
1,042,198
+1,025,993
+6,331% +$23.7M 0.03% 598
2026
Q1
$511K Buy
+16,205
New +$324K ﹤0.01% 2359
2021
Q2
– Sell
-1,380
Closed -$401K – 2317
2021
Q1
$401K Buy
+1,380
New +$462K ﹤0.01% 1451

Other funds holding FTH

Balyasny Asset Management's FTH Position: Q3 2026 in Review

Balyasny Asset Management increased its Faeth Therapeutics (FTH) stake by 11% in Q3 2026, buying an estimated $3.46M and bringing the position to 1,153,377 shares worth $34.3M. The position accounts for 0.04% of the portfolio, ranked #536.

Balyasny Asset Management first reported a position in FTH in Q1 2021 and has held it in 4 quarters since. 79 funds tracked by Wall St. Rank hold FTH as of Q3 2026.

  • Balyasny Asset Management held 1,153,377 shares of Faeth Therapeutics worth $34.3M as of Q3 2026.
  • Balyasny Asset Management bought 111,179 Faeth Therapeutics shares in Q3 2026, an estimated $3.46M.
  • Faeth Therapeutics made up 0.04% of Balyasny Asset Management's portfolio in Q3 2026, its #536 holding.
  • Balyasny Asset Management first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • 79 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.